A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Malmer B, Iselius L, Holmberg E, Collins A, Henriksson R, Grönberg H. Genetic epidemiology of glioma. Br J Cancer 2001;84:429–34.
   PubMed Web of Science ®Google Scholar
• Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, . Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008;40:631–7.
   PubMed Web of Science ®Google Scholar
• Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, . Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:702–5.
   PubMed Web of Science ®Google Scholar
• Malmer BS, Feychting M, Lönn S, Lindström S, Grönberg H, Ahlbom A, . Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol 2007;82:229–37.
   PubMedGoogle Scholar
• Bethke L, Webb E, Murray A, Schoemaker M, Johansen C, Christensen HC, . Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Hum Mol Genet 2008;17:800–5.
   PubMedGoogle Scholar
• Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, . Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 2008.
   PubMedGoogle Scholar
• Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, Pico AR, . Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 2008;17:1368–73.
   PubMed Web of Science ®Google Scholar
• Collins VP. Mechanisms of disease: Genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 2007;4:362–74.
   PubMedGoogle Scholar
• Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, . A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727–31.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445–53.
   PubMed Web of Science ®Google Scholar
• Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, . LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. Embo J 2004;23:3270–81.
   PubMed Web of Science ®Google Scholar
• Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling–double-edged swords in human cancer? Eur J Cancer 2007;43:676–82.
   PubMed Web of Science ®Google Scholar
• Johansson M, Brännström T, Bergenheim AT, Henriksson R. Spatial expression of VEGF-A in human glioma. J Neurooncol 2002;59:1–6.
   PubMed Web of Science ®Google Scholar
• Maity A, Pore N, Lee J, Solomon D, O’Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3’-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879–86.
   PubMed Web of Science ®Google Scholar
• Schwartzbaum JA, Ahlbom A, Lönn S, Warholm M, Rannug A, Auvinen A, . An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 2007;16:559–65.
   PubMedGoogle Scholar
• Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, . The INTERPHONE study: Design, epidemiological methods, and description of the study population. Eur J Epidemiol 2007;22:647–64.
   PubMed Web of Science ®Google Scholar
• Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, . Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41: 899–904.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, . A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870–4.
   PubMed Web of Science ®Google Scholar
• Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, . Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645–9.
   PubMed Web of Science ®Google Scholar
• Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, . Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854–7.
   PubMed Web of Science ®Google Scholar
• Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434–42.
   PubMed Web of Science ®Google Scholar
• Kraft P. Efficient two-stage genome-wide association designs based on false positive report probabilities. Pac Symp Biocomput 2006:523–34.
   PubMedGoogle Scholar
• Hoh J, Hodge SE. A measure of phase ambiguity in pairs of SNPs in the presence of linkage disequilibrium. Hum Hered 2000;50:359–64.
   PubMedGoogle Scholar
• Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, , Cook EH Jr. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46–53.
   PubMed Web of Science ®Google Scholar
• Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, . Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence–first results of an inter-ethnic breast cancer study. J Pathol 2004;203:545–50.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, . Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 2007;13(22 Pt 1):6788–95.
   PubMedGoogle Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–5.
   PubMed Web of Science ®Google Scholar
• Stutz MA, Shattuck DL, Laederich MB, , Carraway KL 3rdSweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008;27:5741–52.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kita D, Favereaux A, Huang H, Homma T, Dessen P, . Brain tumors in S100beta-v-erbB transgenic rats. J Neuropathol Exp Neurol 2006;65:1111–7.
   PubMedGoogle Scholar
• Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, . Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63: 1589–95.
   PubMed Web of Science ®Google Scholar
• Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, . Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 2006;67:872–4.
   PubMedGoogle Scholar
• Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, . Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004;108:135–42.
   PubMed Web of Science ®Google Scholar
• McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, . Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061–8.
   PubMedGoogle Scholar
• Yu H, Gong X, Luo X, Han W, Hong G, Singh B, . Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 2008;7.
   Google Scholar